These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1006 related items for PubMed ID: 17443000

  • 1. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial.
    Schmidt H, Suciu S, Punt CJ, Gore M, Kruit W, Patel P, Lienard D, von der Maase H, Eggermont AM, Keilholz U, American Joint Committee on Cancer Stage IV Melanoma, EORTC 18951.
    J Clin Oncol; 2007 Apr 20; 25(12):1562-9. PubMed ID: 17443000
    [Abstract] [Full Text] [Related]

  • 2. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
    Minor DR, Moore D, Kim C, Kashani-Sabet M, Venna SS, Wang W, Boasberg P, O'Day S.
    Oncologist; 2009 Oct 20; 14(10):995-1002. PubMed ID: 19776094
    [Abstract] [Full Text] [Related]

  • 3. Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03.
    Teramukai S, Kitano T, Kishida Y, Kawahara M, Kubota K, Komuta K, Minato K, Mio T, Fujita Y, Yonei T, Nakano K, Tsuboi M, Shibata K, Furuse K, Fukushima M.
    Eur J Cancer; 2009 Jul 20; 45(11):1950-8. PubMed ID: 19231158
    [Abstract] [Full Text] [Related]

  • 4. LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951).
    Agarwala SS, Keilholz U, Gilles E, Bedikian AY, Wu J, Kay R, Stein CA, Itri LM, Suciu S, Eggermont AM.
    Eur J Cancer; 2009 Jul 20; 45(10):1807-14. PubMed ID: 19419855
    [Abstract] [Full Text] [Related]

  • 5. Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study.
    Finn RS, Gagnon R, Di Leo A, Press MF, Arbushites M, Koehler M.
    J Clin Oncol; 2009 Nov 20; 27(33):5552-8. PubMed ID: 19858400
    [Abstract] [Full Text] [Related]

  • 6. Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model.
    Schmidt H, Bastholt L, Geertsen P, Christensen IJ, Larsen S, Gehl J, von der Maase H.
    Br J Cancer; 2005 Aug 08; 93(3):273-8. PubMed ID: 16052222
    [Abstract] [Full Text] [Related]

  • 7. Long-term survival analysis in metastatic melanoma: serum S100B is an independent prognostic marker and superior to LDH.
    Egberts F, Pollex A, Egberts JH, Kaehler KC, Weichenthal M, Hauschild A.
    Onkologie; 2008 Jul 08; 31(7):380-4. PubMed ID: 18596385
    [Abstract] [Full Text] [Related]

  • 8. Pilot study of high-dose, concurrent biochemotherapy for advanced melanoma.
    Kim KB, Eton O, East MJ, Hodges C, Papadopoulos NE, Grimm EA, Bedikian AY.
    Cancer; 2004 Aug 01; 101(3):596-603. PubMed ID: 15274073
    [Abstract] [Full Text] [Related]

  • 9. A single-institution validation of the AJCC staging system for stage IV melanoma.
    Neuman HB, Patel A, Ishill N, Hanlon C, Brady MS, Halpern AC, Houghton A, Coit DG.
    Ann Surg Oncol; 2008 Jul 01; 15(7):2034-41. PubMed ID: 18465172
    [Abstract] [Full Text] [Related]

  • 10. Prognostic value of blood eosinophilia in primary cutaneous T-cell lymphomas.
    Tancrède-Bohin E, Ionescu MA, de La Salmonière P, Dupuy A, Rivet J, Rybojad M, Dubertret L, Bachelez H, Lebbé C, Morel P.
    Arch Dermatol; 2004 Sep 01; 140(9):1057-61. PubMed ID: 15381544
    [Abstract] [Full Text] [Related]

  • 11. Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and Treatment of Cancer.
    Efficace F, Innominato PF, Bjarnason G, Coens C, Humblet Y, Tumolo S, Genet D, Tampellini M, Bottomley A, Garufi C, Focan C, Giacchetti S, Lévi F, Chronotherapy Group of the European Organisation for Research and Treatment of Cancer.
    J Clin Oncol; 2008 Apr 20; 26(12):2020-6. PubMed ID: 18421055
    [Abstract] [Full Text] [Related]

  • 12. Correlation of positive RT-PCR for tyrosinase in peripheral blood of malignant melanoma patients with clinical stage, survival and other risk factors.
    Proebstle TM, Jiang W, Högel J, Keilholz U, Weber L, Voit C.
    Br J Cancer; 2000 Jan 20; 82(1):118-23. PubMed ID: 10638977
    [Abstract] [Full Text] [Related]

  • 13. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
    Nowecki ZI, Rutkowski P, Kulik J, Siedlecki JA, Ruka W.
    Br J Dermatol; 2008 Sep 20; 159(3):597-605. PubMed ID: 18616789
    [Abstract] [Full Text] [Related]

  • 14. Prognostic factors in 1,521 melanoma patients with distant metastases.
    Barth A, Wanek LA, Morton DL.
    J Am Coll Surg; 1995 Sep 20; 181(3):193-201. PubMed ID: 7670677
    [Abstract] [Full Text] [Related]

  • 15. Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma.
    Bedikian AY, Johnson MM, Warneke CL, Papadopoulos NE, Kim K, Hwu WJ, McIntyre S, Hwu P.
    Cancer Invest; 2008 Jul 20; 26(6):624-33. PubMed ID: 18584354
    [Abstract] [Full Text] [Related]

  • 16. Molecular staging in stage II and III melanoma patients and its effect on long-term survival.
    Voit C, Kron M, Rademaker J, Schwürzer-Voit M, Sterry W, Weber L, Ozdemir C, Proebstle T, Keilholz U.
    J Clin Oncol; 2005 Feb 20; 23(6):1218-27. PubMed ID: 15718319
    [Abstract] [Full Text] [Related]

  • 17. Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study.
    Liu D, O'Day SJ, Yang D, Boasberg P, Milford R, Kristedja T, Groshen S, Weber J.
    Clin Cancer Res; 2005 Feb 01; 11(3):1237-46. PubMed ID: 15709194
    [Abstract] [Full Text] [Related]

  • 18. TA90 immune complex predicts survival following surgery and adjuvant vaccine immunotherapy for stage IV melanoma.
    Hsueh EC, Gupta RK, Qi K, Yee R, Leopoldo ZC, Morton DL.
    Cancer J Sci Am; 1997 Feb 01; 3(6):364-70. PubMed ID: 9403050
    [Abstract] [Full Text] [Related]

  • 19. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group.
    Keilholz U, Punt CJ, Gore M, Kruit W, Patel P, Lienard D, Thomas J, Proebstle TM, Schmittel A, Schadendorf D, Velu T, Negrier S, Kleeberg U, Lehman F, Suciu S, Eggermont AM.
    J Clin Oncol; 2005 Sep 20; 23(27):6747-55. PubMed ID: 16170182
    [Abstract] [Full Text] [Related]

  • 20. Prognostic significance of tyrosinase mRNA detected by nested RT-PCR in patients with malignant melanoma.
    Glumac N, Snoj M, Hocevar M, Novakovic S.
    Neoplasma; 2006 Sep 20; 53(1):9-14. PubMed ID: 16416006
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.